A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
Epistemonikos ID: 8f2d799761a23a7c87b6e6b3e37f6d543aba871c
First added on: May 22, 2024